These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 32203084)

  • 1. Aloe-emodin exerts cholesterol-lowering effects by inhibiting proprotein convertase subtilisin/kexin type 9 in hyperlipidemic rats.
    Su ZL; Hang PZ; Hu J; Zheng YY; Sun HQ; Guo J; Liu KY; Du ZM
    Acta Pharmacol Sin; 2020 Aug; 41(8):1085-1092. PubMed ID: 32203084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kanglexin, a new anthraquinone compound, attenuates lipid accumulation by activating the AMPK/SREBP-2/PCSK9/LDLR signalling pathway.
    Li X; Hu X; Pan T; Dong L; Ding L; Wang Z; Song R; Wang X; Wang N; Zhang Y; Wang J; Yang B
    Biomed Pharmacother; 2021 Jan; 133():110802. PubMed ID: 33202286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chitosan oligosaccharides enhance lipid droplets via down-regulation of PCSK9 gene expression in HepG2 cells.
    Yang X; Zhang J; Chen L; Wu Q; Yu C
    Exp Cell Res; 2018 May; 366(2):152-160. PubMed ID: 29548750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes.
    Zhang L; McCabe T; Condra JH; Ni YG; Peterson LB; Wang W; Strack AM; Wang F; Pandit S; Hammond H; Wood D; Lewis D; Rosa R; Mendoza V; Cumiskey AM; Johns DG; Hansen BC; Shen X; Geoghagen N; Jensen K; Zhu L; Wietecha K; Wisniewski D; Huang L; Zhao JZ; Ernst R; Hampton R; Haytko P; Ansbro F; Chilewski S; Chin J; Mitnaul LJ; Pellacani A; Sparrow CP; An Z; Strohl W; Hubbard B; Plump AS; Blom D; Sitlani A
    Int J Biol Sci; 2012; 8(3):310-27. PubMed ID: 22355267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ascorbic acid enhances low-density lipoprotein receptor expression by suppressing proprotein convertase subtilisin/kexin 9 expression.
    Wang D; Yang X; Chen Y; Gong K; Yu M; Gao Y; Wu X; Hu H; Liao C; Han J; Duan Y
    J Biol Chem; 2020 Nov; 295(47):15870-15882. PubMed ID: 32913121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
    Sasaki M; Terao Y; Ayaori M; Uto-Kondo H; Iizuka M; Yogo M; Hagisawa K; Takiguchi S; Yakushiji E; Nakaya K; Ogura M; Komatsu T; Ikewaki K
    Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1171-8. PubMed ID: 24675665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel small-molecule PCSK9 inhibitor E28362 ameliorates hyperlipidemia and atherosclerosis.
    Wang WZ; Liu C; Luo JQ; Lei LJ; Chen MH; Zhang YY; Sheng R; Li YN; Wang L; Jiang XH; Xiao TM; Zhang YH; Li SW; Wu YX; Xu Y; Xu YN; Si SY
    Acta Pharmacol Sin; 2024 Oct; 45(10):2119-2133. PubMed ID: 38811775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.
    Urban D; Pöss J; Böhm M; Laufs U
    J Am Coll Cardiol; 2013 Oct; 62(16):1401-8. PubMed ID: 23973703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alginate oligosaccharide enhances LDL uptake via regulation of LDLR and PCSK9 expression.
    Yang JH; Bang MA; Jang CH; Jo GH; Jung SK; Ki SH
    J Nutr Biochem; 2015 Nov; 26(11):1393-400. PubMed ID: 26320675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Electroacupuncture mitigates hyperlipidemia via improving cholesterol metabolism mediated by SCAP/SREBP-2 signaling in liver tissue in rats].
    Wu H; Zhang ZQ; Chen L; Liao S; Wang XF; Lin W
    Zhen Ci Yan Jiu; 2023 Apr; 48(4):325-30. PubMed ID: 37186195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 23,24-Dihydrocucurbitacin B promotes lipid clearance by dual transcriptional regulation of LDLR and PCSK9.
    Li HH; Li J; Zhang XJ; Li JM; Xi C; Wang WQ; Lu YL; Xuan LJ
    Acta Pharmacol Sin; 2020 Mar; 41(3):327-335. PubMed ID: 31358898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of proprotein convertase subtilisin/kexin type 9: a novel mechanism of berberine and 8-hydroxy dihydroberberine against hyperlipidemia.
    Liu DL; Xu LJ; Dong H; Chen G; Huang ZY; Zou X; Wang KF; Luo YH; Lu FE
    Chin J Integr Med; 2015 Feb; 21(2):132-8. PubMed ID: 24893659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Cholesterol-Modulating Effect of Methanol Extract of Pigeon Pea (
    Chang HY; Wu JR; Gao WY; Lin HR; Chen PY; Chen CI; Wu MJ; Yen JH
    Molecules; 2019 Jan; 24(3):. PubMed ID: 30704067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced pro-protein convertase subtilisin/kexin type 9 expression by C-reactive protein through p38MAPK-HNF1α pathway in HepG2 cells.
    Cui CJ; Li S; Zhu CG; Sun J; Du Y; Zhang Y; Wu NQ; Guo YL; Xu RX; Gao Y; Li JJ
    J Cell Mol Med; 2016 Dec; 20(12):2374-2383. PubMed ID: 27633999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gypenoside LVI improves hepatic LDL uptake by decreasing PCSK9 and upregulating LDLR expression.
    Wang J; Wang YS; Huang YP; Jiang CH; Gao M; Zheng X; Yin ZQ; Zhang J
    Phytomedicine; 2021 Oct; 91():153688. PubMed ID: 34380071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice.
    Sun L; Yang X; Li Q; Zeng P; Liu Y; Liu L; Chen Y; Yu M; Ma C; Li X; Li Y; Zhang R; Zhu Y; Miao QR; Han J; Duan Y
    Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):1290-1300. PubMed ID: 28546220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regulation of PCSK9 by nutraceuticals.
    Momtazi AA; Banach M; Pirro M; Katsiki N; Sahebkar A
    Pharmacol Res; 2017 Jun; 120():157-169. PubMed ID: 28363723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulatory mechanism of mineral-balanced deep sea water on hypocholesterolemic effects in HepG2 hepatic cells.
    Lee KS; Kwon YS; Kim S; Moon DS; Kim HJ; Nam KS
    Biomed Pharmacother; 2017 Feb; 86():405-413. PubMed ID: 28012395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New CETP inhibitor K-312 reduces PCSK9 expression: a potential effect on LDL cholesterol metabolism.
    Miyosawa K; Watanabe Y; Murakami K; Murakami T; Shibata H; Iwashita M; Yamazaki H; Yamazaki K; Ohgiya T; Shibuya K; Mizuno K; Tanabe S; Singh SA; Aikawa M
    Am J Physiol Endocrinol Metab; 2015 Jul; 309(2):E177-90. PubMed ID: 26015437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression: a randomized trial in healthy men.
    Gouni-Berthold I; Berthold HK; Gylling H; Hallikainen M; Giannakidou E; Stier S; Ko Y; Patel D; Soutar AK; Seedorf U; Mantzoros CS; Plat J; Krone W
    Atherosclerosis; 2008 May; 198(1):198-207. PubMed ID: 17980884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.